Protein / target
P2Y purinoceptor 12
Protein at a glance
Biological role
G protein-coupled purinergic nucleotide receptor activity
Strongest disease association
platelet-type bleeding disorder 8
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
12 approved · 3 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Receptor for ADP and ATP coupled to G proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation
Subcellular location
Domains and Gene Ontology detail (31)Hide
Gene Ontology
- Ccell body membrane
- Ccell projection membrane
- Ccell surface
- Cmembrane
- Cplasma membrane
- FG protein-coupled adenosine receptor activity
- FG protein-coupled ADP receptor activity
- FG protein-coupled purinergic nucleotide receptor activity
- Fguanyl-nucleotide exchange factor activity
- Padenylate cyclase-inhibiting G protein-coupled receptor signaling pathway
- Pcalcium-mediated signaling
- Pcell projection organization
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Haemostasis
- ·Receptor for ADP and ATP coupled to G proteins that inhibit the adenylyl cyclase second…
- ·hemostasis
- ·platelet activation
- ·platelet aggregation
G protein-coupled signalling
- ·G protein-coupled adenosine receptor activity
- ·G protein-coupled ADP receptor activity
- ·G protein-coupled purinergic nucleotide receptor activity
- ·adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway
Kinase signalling
- ·positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
Immune signalling
- ·substrate-dependent cell migration, cell extension
Cell adhesion
- ·positive regulation of cell adhesion mediated by integrin
View underlying pathways (3)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Purinergic receptor P2Y12 negative allosteric modulator
Appears in clinical studies involving acute coronary syndrome, type 2 diabetes mellitus, coronary artery disorder, myocardial infarction
Purinergic receptor P2Y12 antagonist
Appears in clinical studies involving myocardial infarction, myocardial ischemia, acute coronary syndrome, angina unstable
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 482 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 15 total
acute coronary syndrome · type 2 diabetes mellitus · coronary artery disorder
myocardial infarction
myocardial infarction · Recurrent thrombophlebitis
myocardial infarction · myocardial ischemia · acute coronary syndrome
acute coronary syndrome · peripheral vascular disease · myocardial infarction
Recurrent thrombophlebitis · thrombotic disease · acute coronary syndrome
thrombotic disease · stroke disorder
acute myocardial infarction · Non-ST Elevation Myocardial Infarction
Recurrent thrombophlebitis · Stroke · angina pectoris
Recurrent thrombophlebitis · acute coronary syndrome · myocardial infarction
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 2 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- New publicationEffect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
- New publicationA Genotype-Guided Strategy for Oral P2Y<sub>12</sub> Inhibitors in Primary PCI.
- New publicationTicagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
- New publicationEffect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
- New publicationPrehospital ticagrelor in ST-segment elevation myocardial infarction.
- Regulatory approval
Approval: Brilique (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.